Researchers have found in a new study that among patients with subclinical atrial fibrillation (SCAF), apixaban caused more ...

CLINICAL QUESTION: Does apixaban reduce the risk of stroke or systemic embolism compared to aspirin in patients with subclinical atrial fibrillation and elevated stroke risk? BACKGROUND: Subclinical ...

The above headline recently appeared in the March edition of the American Automotive Association’s (AAA) Explorer Magazine. The same ad contained a table comparing prices of popularly prescribed ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

A NEW study has shown that extended treatment with a reduced dose of apixaban can effectively prevent recurrent venous thromboembolism (VTE) in cancer patients while reducing the risk of bleeding.

Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of ...

A SUBGROUP analysis of the ARTESiA trial suggests that apixaban provides a significant reduction in stroke or systemic embolism in people with subclinical atrial fibrillation and a history of stroke ...

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot ...

Background: Data on off-label reduced dose risk among patients with atrial fibrillation (AF) who qualify for a single-dose reduction of apixaban is scarce. Objectives: We prospectively assessed ...